Piper Sandler Maintains Overweight on Immunovant, Raises Price Target to $57
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst Yasmeen Rahimi maintains an Overweight rating on Immunovant (NASDAQ:IMVT) and raises the price target from $28 to $57.
October 24, 2023 | 3:46 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Piper Sandler has maintained an Overweight rating on Immunovant and raised the price target from $28 to $57.
The raised price target by Piper Sandler indicates a positive outlook for Immunovant. This could lead to increased investor confidence and potentially a rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100